Bajaj Healthcare is currently trading at Rs. 679.35, up by 22.95 points or 3.50% from its previous closing of Rs. 656.40 on the BSE.
The scrip opened at Rs. 648.95 and has touched a high and low of Rs. 681.40 and Rs. 639.55 respectively. So far 52670 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 5 has touched a 52 week high of Rs. 689.95 on 20-Jan-2025 and a 52 week low of Rs. 265.00 on 04-Jun-2024.
Last one week high and low of the scrip stood at Rs. 689.00 and Rs. 510.00 respectively. The current market cap of the company is Rs. 2101.23 crore.
The promoters holding in the company stood at 59.19%, while Institutions and Non-Institutions held 3.37% and 37.45% respectively.
Bajaj Healthcare has received approval from the Drug Controller General of India (DCGI) to manufacture both the API and Drug Formulation of Pimavanserin, a 34 mg capsule. Pimavanserin is an atypical antipsychotic used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Pimavanserin, marketed globally as NUPLAZID, has become a preferred treatment in the US antipsychotic segment. In a recent update, Acadia Pharmaceuticals announced that NUPLAZID, along with its other brand DAYBUE, is projected to generate more than $1 billion in net sales in 2025.
The company has also extended offer for Pimavanserin to several leading Indian pharmaceutical companies, ensuring the product’s availability in the domestic market.
Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1714.25 |
Dr. Reddys Lab | 1149.75 |
Cipla | 1452.70 |
Lupin | 2009.40 |
Zydus Lifesciences | 891.25 |
View more.. |